Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
14th January 2021 | William Hewitt Robinson | 2,259 | Open or private sale | $15.06 | $34,010.83 |
13th January 2021 | William Hewitt Robinson | 2,741 | Open or private sale | $15.05 | $41,238.62 |
4th January 2021 | Bros. Advisors Lp Baker | 10,060 | Open or private sale | $220.50 | $2,218,230.00 |
4th January 2021 | Bros. Advisors Lp Baker | 111,094 | Open or private sale | $220.50 | $24,496,227.00 |
31st December 2020 | Bros. Advisors Lp Baker | 343 | Grant/award etc. | $0.00 | |
31st December 2020 | Bros. Advisors Lp Baker | 343 | Grant/award etc. | $0.00 | |
17th December 2020 | Norman Michael Greenberg | 5,000 | Exercise of derivative | $4.56 | $22,800.00 |
17th December 2020 | Norman Michael Greenberg | 5,000 | Open or private sale | $16.61 | $83,051.00 |
11th December 2020 | Tito Serafini | 10,000 | Open or private sale | $15.87 | $158,735.00 |
4th December 2020 | Bros. Advisors Lp Baker | 125,513 | Open or private sale | $220.50 | $27,675,616.50 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 3/10.
Atreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients.
8th December 2020
6th November 2020
6th November 2020
6th November 2020